You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Second primary site disease stage III

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Radiotherapy Combined With EGFR-TKI for Stage III EGFR Mutant

Completed
  • The Primary Study Metric is Progression-free Survival (PFS)
    • (no location specified)
    Jun 28, 2023

    Stage III Gastric Cancer Trial in Nanjing (ONS)

    Not yet recruiting
    • Stage III Gastric Cancer
    • ONS
    • Nanjing, Jiangsu, China
      Jinling Hospital, China
    Jul 25, 2022

    Epithelial Ovarian Carcinoma Stage III, Epithelial Ovarian Carcinoma Stage IV, Fallopian Tube Carcinoma Stage III Trial in China

    Recruiting
    • Epithelial Ovarian Carcinoma Stage III
    • +5 more
    • nab-paclitaxel combined with carboplatin
    • Guangzhou, Guangdong, China
    • +10 more
    Feb 19, 2023

    Non Small Cell Lung Cancer (Stage III) Trial in Worldwide (Osimertinib 80mg/40mg, Placebo Osimertinib 80mg/40mg)

    Active, not recruiting
    • Non Small Cell Lung Cancer (Stage III)
    • Osimertinib 80mg/40mg
    • Placebo Osimertinib 80mg/40mg
    • Duarte, California
    • +116 more
    Jan 23, 2023

    Gastric Adenocarcinoma Trial in Saint-Herblain (Preoperative Chemotherapy, Surgery, Postoperative chemo)

    Recruiting
    • Gastric Adenocarcinoma
    • Preoperative Chemotherapy
    • +2 more
    • Saint-Herblain, France
      Ico - Site Gauducheau - St Herblain
    Mar 14, 2022

    Peripheral Arterial Disease Trial in Shanghai

    Recruiting
    • Peripheral Arterial Disease
      • Shanghai, China
        Zhongshan Hospital, Fudan University
      Oct 26, 2022

      Breast Cancer Trial in Worldwide (Dato-DXd, Durvalumab, Capecitabine)

      Recruiting
      • Breast Cancer
      • Gilbert, Arizona
      • +165 more
      Jan 17, 2023

      Castration-Resistant Prostate Carcinoma, Metastatic Malignant Tumor in the Bone, Metastatic Malignant Tumor in the Soft Tissues

      Active, not recruiting
      Has Results
      • Castration-Resistant Prostate Carcinoma
      • +6 more
      • San Francisco, California
      • +1 more
      Sep 20, 2022

      Palliative Primary Tumor Resection in Minimally Symptomatic

      Recruiting
      • Colorectal Neoplasms
      • +12 more
      • Moscow, Russian Federation
        Ryzhikh National Medical Research Center of Coloproctology
      Apr 2, 2022

      Advanced Cholangiocarcinoma, Advanced Hepatocellular Carcinoma, Advanced Malignant Solid Tumor Trial in Los Angeles (Biospecimen

      Recruiting
      • Advanced Cholangiocarcinoma
      • +6 more
      • Biospecimen Collection
      • +3 more
      • Los Angeles, California
      • +1 more
      Mar 31, 2023

      Fallopian Tube Serous Adenocarcinoma, High Grade Ovarian Serous Adenocarcinoma, Ovarian Mass Trial in United States (Laboratory

      Completed
      • Fallopian Tube Serous Adenocarcinoma
      • +18 more
      • Laboratory Biomarker Analysis
      • BMN 673
      • Houston, Texas
      • +5 more
      Feb 11, 2022

      Carcinoma, Non- Small Cell Lung Trial in Worldwide (Durvalumab, Placebo)

      Active, not recruiting
      • Carcinoma, Non- Small Cell Lung
      • Long Beach, California
      • +117 more
      Oct 18, 2022

      NSCLC Trial in Worldwide (Durvalumab, Domvanalimab, Placebo)

      Recruiting
      • Non-Small Cell Lung Cancer
      • Mesa, Arizona
      • +128 more
      Aug 10, 2022

      Hodgkin Lymphoma Trial in United Kingdom (Involved site radiotherapy, Doxorubicin, Bleomycin)

      Recruiting
      • Hodgkin Lymphoma
      • Involved site radiotherapy
      • +6 more
      • Aberdeen, United Kingdom
      • +6 more
      May 24, 2022

      Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck, Resectable Cutaneous Squamous Cell Carcinoma of the

      Recruiting
      • Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck
      • +2 more
      • Atezolizumab
      • +2 more
      • Sacramento, California
        University of California Davis Comprehensive Cancer Center
      Jan 19, 2022

      Limited-Stage Small Cell Lung Cancer Trial in Jinan (HLX10, carboplatin/cisplatin-etoposide, Thoracic radiotherapy)

      Recruiting
      • Limited-Stage Small Cell Lung Cancer
      • Anaheim, California
      • +83 more
      Jan 12, 2023

      Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in

      Active, not recruiting
      • Accelerated Phase Chronic Myelogenous Leukemia
      • +125 more
      • tetanus-CMV fusion peptide vaccine
      • laboratory biomarker analysis
      • Duarte, California
        City of Hope Medical Center
      Feb 28, 2022

      COVID-19 Trial in Worldwide (SARS-CoV-2 adjuvanted recombinant protein vaccine (monovalent), SARS-CoV-2 adjuvanted recombinant

      Active, not recruiting
      • COVID-19
      • SARS-CoV-2 adjuvanted recombinant protein vaccine (monovalent)
      • +2 more
      • Birmingham, Alabama
      • +93 more
      Jul 22, 2022

      Liver Diseases, Liver Cancer, Liver Metastases Trial in Murcia (Liver Transplantation)

      Not yet recruiting
      • Liver Diseases
      • +27 more
      • Liver Transplantation
      • Murcia, Spain
        Felipe Alconchel
      Feb 24, 2022

      Small Cell Lung Carcinoma Extensive Disease Trial in Worldwide (Durvalumab, Tremelimumab, Carboplatin)

      Active, not recruiting
      Has Results
      • Small Cell Lung Carcinoma Extensive Disease
      • Birmingham, Alabama
      • +205 more
      Mar 11, 2022

      EVALUATION OF MACROPHAGE INFLAMMATORY PROTEIN-1a AS A

      Not yet recruiting
      • Periodontitis Chronic Generalized Severe
      • +2 more
        • Rohtak, Haryana, India
          Post Graduate Institute of Dental Sciences
        Aug 23, 2023

        Metastatic NSCLC Trial in France (Pembrolizumab before randomization, Chemotherapy, Pemetrexed)

        Recruiting
        • Metastatic NSCLC
        • Pembrolizumab before randomization
        • +3 more
        • Aix-en-Provence, France
        • +37 more
        Jul 26, 2022

        Breast Tumors Trial in Shenyang (Next-generation Site-specific human epidermal growth factor receptor 2 (HER2)-targeting

        Recruiting
        • Breast Neoplasms
        • Next-generation Site-specific human epidermal growth factor receptor 2 (HER2)-targeting Antibody-drug Conjugate (ARX788)
        • Shenyang, Liaoning, China
          Shengjing Hospital affiliated to China Medical University
        Jul 30, 2022

        Primary Hyperoxaluria, Primary Hyperoxaluria Type 2, End Stage Renal Disease Trial in Spain, United Kingdom, United States

        Recruiting
        • Primary Hyperoxaluria
        • +2 more
        • Rochester, Minnesota
        • +4 more
        Jul 7, 2021

        Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV Trial in Worldwide (Selumetinib, Docetaxel, Placebo)

        Active, not recruiting
        Has Results
        • Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV
        • Aurora, Colorado
        • +196 more
        Dec 22, 2022